Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CEACAM-5

CEACAM-5

Brief Information

Name:Carcinoembryonic antigen related cell adhesion molecule 5
Target Synonym:CEA Cell Adhesion Molecule 5,CEACAM5,Meconium antigen 100,CEA,Carcinoembryonic Antigen Related Cell Adhesion Molecule 5,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5,Carcinoembryonic Antigen,CD66e Antigen,CD66e
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

CE5-H82E0-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-CEACAM-5 (labetuzumab) Antibody, Human IgG1 captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Biotinylated Human CEACAM-5, His,Avitag (Cat. No. CE5-H82E0) with an affinity constant of 12.1 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CE5-H5226-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-CEACAM-5 (labetuzumab) Antibody, Human IgG1 captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CEACAM-5, His Tag (Cat. No. CE5-H5226) with an affinity constant of 8.41 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Synonym Name

CEACAM-5,CD66e,CEA,Meconium antigen 100

Background

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is also Carcinoembryonic antigen (CEA), Meconium antigen 100, CD antigen CD66e, CEACAM5 belongs to the immunoglobulin superfamily and CEA family. CEACAM5 contains seven Ig-like (immunoglobulin-like) domains. CEACAM5 is homodimer protein which binding of E.coli Dr adhesins leads to dissociation of the homodimer. CEACAM5 is cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. CEACAM5 is receptor for E.coli Dr adhesins.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
TF 2-targeted cancer therapy TF-2 Phase 2 Clinical Immunomedics, Ibc Pharmaceuticals Small Cell Lung Carcinoma; Mastocytosis, Cutaneous; Breast Neoplasms; Colorectal Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung Details
NEO-201 NEO-201 Phase 2 Clinical Precision Biologics, National Cancer Institute Squamous Cell Carcinoma of Head and Neck; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
SGM-101 SGM-101 Phase 3 Clinical Surgimab Stomach Neoplasms; Rectal Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms Details
Labetuzumab govitecan IMMU-130; hMN-14-SN38 Phase 2 Clinical Immunomedics, Ibc Pharmaceuticals Rectal Neoplasms; Colonic Neoplasms; Breast Neoplasms; Colorectal Neoplasms Details
Carcinoembryonic antigen autologous dendritic cell vaccine (Duke University) Phase 2 Clinical Duke University Neoplasms Details
Anti-CEA CAR T cell therapy (Shanghai GeneChem) Phase 2 Clinical Shanghai Genechem Co Ltd, The First Affiliated Hospital of Air Force Medical University Liver Neoplasms; Colorectal Neoplasms Details
Recombinant Saccharomyces cerevisiae-CEA GI-6207 Phase 2 Clinical Globeimmune Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Medullary thyroid cancer (MTC); Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) CVAC-301; CV-301 Phase 3 Clinical Therion Biologics Ovarian Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Cibisatamab CEA-TCB; RG-7802; RO-6958688; CEA-CD3 TCB Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Tusamitamab Ravtansine SAR-408701 Phase 3 Clinical Immunogen Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
MFE-23-CD3z T cell therapy (Cancer Research Technology) Phase 1 Clinical Cancer Research Technology Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message